Skip to main content

Table 1 Patients’ baseline laboratory, ultrasonographic, and endoscopic features

From: Predictors of residual hepatic reserve and hepatic decompensation in cirrhotic patients after ablated hepatocellular carcinoma treated by DDAs or systemic therapy

Variable

Patients (n= 500)

Age

44.3 ± 3.6

M/F

378/122

ALT (IU/L)

62.9± 10.5

AST (IU/L)

64.8 ± 11

Albumin (gm/dl)

3.48± 0.46

γ- globulin (gm/dl)

3.83±0.48

Total bilirubin (mg/dl)

1.32 ± 0.27

Platelet count (103/ul)

89.1 ± 17.2

PDW/MPV

3.06±0.75

PC

57.4 ± 6.7

Creatinine (mg/dl)

1.14 ± 0.23

Ammonia (ug/dl)

80.55 ± 22.5

Sodium (meq/L)

137.8 ± 4.7

MELD

14.57 ± 3.5

CTP

6

HCV-RNA KIU/ml

588.6 ± 127

Radiological Signs

- Fibroscan (kPa)

24.07 ± 5.5

 -Liver volume (ml)

575.57 ± 84.3

Upper endoscopy

GI-II esophageal varices (EVs)

112 (22.4%)

GIII-IV EVs

86 (17.2%)

Fundal varices

45 (9%)

  1. PDW/MPV Platelet distribution width/mean platelet volume, PC Prothrombin concentration, CTP Child Turcotte Pugh score, MELD Model for end stage liver disease, EVs Esophageal varices